Johnson & Johnson (JNJ)[Tv]

Key Developments

• FDA De Novo approval of OTTAVA™ Robotic Surgical System – This landmark regulatory milestone marks Johnson & Johnson’s bold entry into the $60B+ surgical robotics market, directly challenging Intuitive Surgical and signaling a transformative pivot from traditional pharma to high-growth medtech.
• $5.5 billion talc settlement framework approved by court, pending claimant approval – This resolution of a 15-year legal battle removes a decades-long liability overhang, enabling strategic focus on innovation and capital allocation, though final approval remains uncertain.
• Record Q2 2026 results: $25.31B revenue, $2.90 EPS, $101.1B full-year guidance – JNJ delivered its strongest quarterly performance ever, surpassing expectations and making it the first time the company is on track to exceed $100B in annual revenue.
• Aggressive expansion into next-gen therapies and medtech platforms, including $785M investment in Sail Biomedicines – The company is doubling down on high-risk, high-reward innovation in areas like in vivo CAR-T and pulsed-field ablation, signaling long-term growth ambitions beyond traditional pharma.
• Strategic leadership shift: Tom Cavanaugh appointed to lead Innovative Medicine, Jennifer Taubert’s departure – While Cavanaugh’s appointment signals continuity, the exit of oncology visionary Taubert introduces a critical leadership void during a pivotal innovation phase.